Kallistatin deficiency exacerbates neuronal damage after cardiac arrest

The purpose of study was to evaluate that kallistatin deficiency causes excessive production of reactive oxygen species and exacerbates neuronal injury after cardiac arrest. For in vitro study, kallistatin knockdown human neuronal cells were given ischemia–reperfusion injury, and the oxidative stress and apoptosis were evaluated. For clinical study, cardiac arrest survivors admitted to the ICU were divided into the good (CPC 1–2) and poor (CPC 3–5) 6-month neurological outcome groups. The serum level of kallistatin, Nox-1, H 2 O 2 were measured. Nox-1 and H 2 O 2 levels were increased in the kallistatin knockdown human neuronal cells with ischemia–reperfusion injury (p < 0.001) and caspase-3 was elevated and apoptosis was promoted (SERPINA4 siRNA: p < 0.01). Among a total of 62 cardiac arrest survivors (16 good, 46 poor), serum kallistatin were lower, and Nox-1 were higher in the poor neurological group at all time points after admission to the ICU ( p = 0.013 at admission; p = 0.020 at 24 h; p = 0.011 at 72 h). At 72 h, H 2 O 2 were higher in the poor neurological group ( p = 0.038). Kallistatin deficiency exacerbates neuronal ischemia–reperfusion injury and low serum kallistatin levels were associated with poor neurological outcomes in cardiac arrest survivors.